Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    FDA Clears Cepheid’s Influenza, RSV Diagnostic

    By Global Biodefense StaffNovember 25, 2014
    Influenza Surveillance and Preparedness
    Share
    Facebook LinkedIn Reddit Email

    Cepheid this week announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert Flu/RSV XC, an on-demand molecular test for diagnosis of Flu A, Flu B, and differentiation of RSV infection.

    The assay runs on Cepheid’s GeneXpert System, which has a worldwide install base of more than 7,500 systems.

    Upper respiratory infections are one of the most common reasons for doctor and hospital visits and, in the United States, are the most common illness leading to school or work absences. Early symptoms for a wide variety of viral and bacterial respiratory infections are similar, yet treatment is different depending on the cause of infection.

    With Xpert Flu/RSV XC, hospitals and clinicians can reliably diagnose and differentiate influenza strains and RSV in real-time.

    “Influenza strains are notoriously unpredictable and the severity of flu outbreaks can vary widely from season to season,” said John Bishop, Cepheid’s Chairman and Chief Executive Officer. “Recent media coverage of serious viruses such as Enterovirus D68 and Ebola have raised public awareness, and created a greater need for healthcare workers to deliver timely and accurate test results for flu or RSV infection.”

    Source: Cepheid press release, adapted. Xpert and GeneXpert are registered, protected terms by Cepheid.

    Influenza RSV
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleRFI for National Security Research Topics
    Next Article IDRI to Advance Thermostable TB Vaccine

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    Pandemic Flu Has Many Potential Pathways

    October 19, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.